Potential biomarkers of recurrent FSGS: a review.
Biomarkers
Focal segmental glomerulosclerosis
Pathogenesis
Pathophysiology
Relapse
Renal transplantation
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
12 Aug 2024
12 Aug 2024
Historique:
received:
06
05
2024
accepted:
05
08
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
12
8
2024
Statut:
epublish
Résumé
Focal segmental glomerulosclerosis (FSGS), a clinicopathological condition characterized by nephrotic-range proteinuria, has a high risk of progression to end-stage renal disease (ESRD). Meanwhile, the recurrence of FSGS after renal transplantation is one of the main causes of graft loss. The diagnosis of recurrent FSGS is mainly based on renal puncture biopsy transplants, an approach not widely consented by patients with early mild disease. Therefore, there is an urgent need to find definitive diagnostic markers that can act as a target for early diagnosis and intervention in the treatment of patients. In this review, we summarize the domestic and international studies on the pathophysiology, pathogenesis and earliest screening methods of FSGS and describe the functions and roles of specific circulating factors in the progression of early FSGS, in order to provide a new theoretical basis for early diagnosis of FSGS recurrence, as well as aid the exploration of therapeutic targets.
Identifiants
pubmed: 39134955
doi: 10.1186/s12882-024-03695-8
pii: 10.1186/s12882-024-03695-8
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
258Informations de copyright
© 2024. The Author(s).
Références
D’Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368–82. https://doi.org/10.1053/j.ajkd.2003.10.024 .
doi: 10.1053/j.ajkd.2003.10.024
pubmed: 14750104
Lanaret C, Anglicheau D, Audard V, et al. Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: results of a nationwide study. Am J Transpl. 2021;21(9):3021–33. https://doi.org/10.1111/ajt.16504 .
doi: 10.1111/ajt.16504
Müller-Deile J, Sarau G, Kotb AM, et al. Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent focal segmental glomerulosclerosis. Sci Rep. 2021;11(1):4577. https://doi.org/10.1038/s41598-021-83883-w .
doi: 10.1038/s41598-021-83883-w
pubmed: 33633212
pmcid: 7907124
Musiała A, Donizy P, Augustyniak-Bartosik H, et al. Biomarkers in primary focal segmental glomerulosclerosis in Optimal Diagnostic-Therapeutic Strategy. J Clin Med. 2022;11(12):3292. https://doi.org/10.3390/jcm11123292 .
doi: 10.3390/jcm11123292
pubmed: 35743361
pmcid: 9225193
Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transpl. 2005;5(6):1179–85. https://doi.org/10.1111/j.1600-6143.2005.00968.x .
doi: 10.1111/j.1600-6143.2005.00968.x
Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12:502–17.
doi: 10.2215/CJN.05960616
pubmed: 28242845
pmcid: 5338705
Kidney Disease. Improving Global Outcomes Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidnet Int Suppl. 2012;2:1–274.
Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol. 2012;74:299–323. https://doi.org/10.1146/annurev-physiol-020911-153238 .
doi: 10.1146/annurev-physiol-020911-153238
pubmed: 22054238
Erichsen L, Thimm C, Bohndorf M, et al. Activation of the renin-angiotensin system disrupts the Cytoskeletal Architecture of Human urine-derived podocytes. Cells. 2022;11(7):1095. https://doi.org/10.3390/cells11071095 .
doi: 10.3390/cells11071095
pubmed: 35406662
pmcid: 8997628
Tryggvason K, Pikkarainen T, Patrakka J. Nck links nephrin to actin in kidney podocytes. Cell. 2006;125(2):221–4. https://doi.org/10.1016/j.cell.2006.04.002 .
doi: 10.1016/j.cell.2006.04.002
pubmed: 16630808
Kravets I, Mallipattu SK. The role of Podocytes and Podocyte-Associated biomarkers in diagnosis and treatment of Diabetic kidney disease. J Endocr Soc. 2020;4(4):bvaa029. https://doi.org/10.1210/jendso/bvaa029 .
doi: 10.1210/jendso/bvaa029
pubmed: 32232184
pmcid: 7093089
Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol. 2015;11(2):76–87. https://doi.org/10.1038/nrneph.2014.216 .
doi: 10.1038/nrneph.2014.216
pubmed: 25447132
Rashmi P, Sigdel TK, Rychkov D, et al. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors. Ann Transl Med. 2023;11(9):315. https://doi.org/10.21037/atm-22-3670 .
doi: 10.21037/atm-22-3670
pubmed: 37404982
pmcid: 10316099
Hoyer JR, Vernier RL, Najarian JS, et al. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet. 1972;2(7773):343–8. https://doi.org/10.1016/s0140-6736(72)91734-5 .
doi: 10.1016/s0140-6736(72)91734-5
pubmed: 4114718
Chang JW, Pardo V, Sageshima J, et al. Podocyte foot process effacement in postreperfusion allograft biopsies correlates with early recurrence of proteinuriain focal segmental glomerulosclerosis. Transplantation. 2012;93(12):1238–44. https://doi.org/10.1097/TP.0b013e318250234a .
doi: 10.1097/TP.0b013e318250234a
pubmed: 22499148
pmcid: 3432300
Gallon L, Leventhal J, Skaro A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med. 2012;366(17):1648–9. https://doi.org/10.1056/NEJMc1202500 .
doi: 10.1056/NEJMc1202500
pubmed: 22533598
Kemper MJ, Wolf G, Müller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med. 2001;344(5):386–7. https://doi.org/10.1056/NEJM200102013440517 .
doi: 10.1056/NEJM200102013440517
pubmed: 11195803
Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334(14):878–83. https://doi.org/10.1056/NEJM199604043341402 .
doi: 10.1056/NEJM199604043341402
pubmed: 8596570
da Silva CA, Araújo LS, Dos Reis Monteiro MLG, et al. Evaluation of the diagnostic potential of uPAR as a biomarker in renal biopsies of patients with FSGS. Dis Markers. 2019;2019:1070495. https://doi.org/10.1155/2019/1070495 .
doi: 10.1155/2019/1070495
pubmed: 31191741
pmcid: 6525920
Hindy G, Tyrrell DJ, Vasbinder A, et al. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis. J Clin Invest. 2022;132(24):e158788. https://doi.org/10.1172/JCI158788 .
doi: 10.1172/JCI158788
pubmed: 36194491
pmcid: 9754000
Manfredi M, Van Hoovels L, Benucci M, et al. Soluble urokinase plasminogen activator receptor (suPAR) in autoimmune rheumatic and non Rheumatic diseases. J Pers Med. 2023;13(4):688. https://doi.org/10.3390/jpm13040688 .
doi: 10.3390/jpm13040688
pubmed: 37109074
pmcid: 10140982
Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952–60. https://doi.org/10.1038/nm.2411 .
doi: 10.1038/nm.2411
pubmed: 21804539
pmcid: 4089394
Alachkar N, Li J, Matar D, et al. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab. BMC Nephrol. 2018;19(1):361. https://doi.org/10.1186/s12882-018-1177-x .
doi: 10.1186/s12882-018-1177-x
pubmed: 30558559
pmcid: 6296111
Hayek SS, Koh KH, Grams ME, et al. A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease. Nat Med. 2017;23(8):945–53. https://doi.org/10.1038/nm.4362 .
doi: 10.1038/nm.4362
pubmed: 28650456
pmcid: 6019326
Kronbichler A, Saleem MA, Meijers B, et al. Soluble urokinase receptors in focal segmental glomerulosclerosis: a review on the Scientific Point of View. J Immunol Res. 2016;2016:2068691. https://doi.org/10.1155/2016/2068691 .
doi: 10.1155/2016/2068691
pubmed: 27504461
pmcid: 4967695
Wieder N, Greka A, Calcium. TRPC channels, and regulation of the actin cytoskeleton in podocytes: towards a future of targeted therapies. Pediatr Nephrol. 2016;31(7):1047–54. https://doi.org/10.1007/s00467-015-3224-1 .
doi: 10.1007/s00467-015-3224-1
pubmed: 26490951
Tian D, Jacobo SM, Billing D, et al. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal. 2010;3(145):ra77. https://doi.org/10.1126/scisignal.2001200 .
doi: 10.1126/scisignal.2001200
pubmed: 20978238
pmcid: 3071756
Crabtree GR, Olson EN. NFAT signaling: choreographing the social lives of cells. Cell. 2002;109(Suppl):S67–79. https://doi.org/10.1016/s0092-8674(02)00699-2 .
Zhang B, Shi W, Ma J, et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J Mol Med (Berl). 2012;90(12):1407–20. https://doi.org/10.1007/s00109-012-0960-6 .
doi: 10.1007/s00109-012-0960-6
pubmed: 23015147
Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3(12):932–43. https://doi.org/10.1038/nrm977 .
doi: 10.1038/nrm977
pubmed: 12461559
Yoo TH, Pedigo CE, Guzman J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015;26(1):133–47. https://doi.org/10.1681/ASN.2013111213 .
doi: 10.1681/ASN.2013111213
pubmed: 24925721
Harel E, Shoji J, Abraham V, et al. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation. Clin Transpl. 2019;33(3):e13487. https://doi.org/10.1111/ctr.13487 .
doi: 10.1111/ctr.13487
Harel E, Shoji J, Abraham V, et al. Further evidence that the Soluble Urokinase Plasminogen activator receptor does not directly injure mice or human podocytes. Transplantation. 2020;104(1):54–60. https://doi.org/10.1097/TP.0000000000002930 .
Rapetskaya NV, Komissarov KS, Kalachik OV. SuPAR-based choice of the management strategy in kidney transplant recipients with infection. Almanac Clin Med. 2020;48(3):187–92.
doi: 10.18786/2072-0505-2020-48-030
Macionyte RS, Bardauskas M, Vaiciuniene R et al. Changes of soluble urokinase plasminogen activator receptor (Supar) after cadaveric kidney transplantation and association with kidney function. Nephrol Dial Transpl. 2021;36(1).
Argiriadi MA, Benatuil L, Dubrovska I, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019;20(1):29. https://doi.org/10.1186/s12860-019-0213-4 .
doi: 10.1186/s12860-019-0213-4
pubmed: 31382872
pmcid: 6683420
Henn V, Steinbach S, Büchner K, et al. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98(4):1047–54. https://doi.org/10.1182/blood.v98.4.1047 .
doi: 10.1182/blood.v98.4.1047
pubmed: 11493450
Doublier S, Zennaro C, Musante L, et al. Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS. PLoS ONE. 2017;12(11):e0188045. https://doi.org/10.1371/journal.pone.0188045 .
doi: 10.1371/journal.pone.0188045
pubmed: 29155846
pmcid: 5695800
Delville M, Sigdel TK, Wei C, et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014;6(256):256ra136. https://doi.org/10.1126/scitranslmed.3008538 .
doi: 10.1126/scitranslmed.3008538
pubmed: 25273097
pmcid: 4394366
Shoji J, Goggins WC, Wellen JR, et al. Efficacy and safety of Bleselumab in preventing the recurrence of primary focal segmental glomerulosclerosis in kidney transplant recipients: a phase 2a, Randomized, Multicenter Study. Transplantation. 2024. https://doi.org/10.1097/TP.0000000000004985 .
doi: 10.1097/TP.0000000000004985
pubmed: 39042770
pmcid: 11262731
Chebotareva N, Cao V, Vinogradov A, et al. Preliminary study of anti-CD40 and ubiquitin proteasome antibodies in primary podocytopaties. Front Med (Lausanne). 2023;10:1189017. https://doi.org/10.3389/fmed.2023.1189017 .
doi: 10.3389/fmed.2023.1189017
pubmed: 37409273
Vincenti F, Klintmalm G, Yang H, et al. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation. Am J Transpl. 2020;20(1):172–80. https://doi.org/10.1111/ajt.15560 .
doi: 10.1111/ajt.15560
Harland RC, Klintmalm G, Jensik S, et al. Efficacy and safety of bleselumab in kidney transplant recipients: a phase 2, randomized, open-label, noninferiority study. Am J Transpl. 2020;20(1):159–71. https://doi.org/10.1111/ajt.15591 .
doi: 10.1111/ajt.15591
Rousseau F, Gauchat JF, McLeod JG, et al. Inactivation of cardiotrophin-like cytokine, a second ligand for ciliary neurotrophic factor receptor, leads to cold-induced sweating syndrome in a patient. Proc Natl Acad Sci U S A. 2006;103(26):10068–73. https://doi.org/10.1073/pnas.0509598103 .
doi: 10.1073/pnas.0509598103
pubmed: 16782820
pmcid: 1502507
Königshausen E, Sellin L. Circulating permeability factors in primary focal segmental glomerulosclerosis: a review of proposed candidates. Biomed Res Int. 2016;2016:3765608. https://doi.org/10.1155/2016/3765608 .
doi: 10.1155/2016/3765608
pubmed: 27200372
pmcid: 4856884
McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(11):2115–21. https://doi.org/10.2215/CJN.03800609 .
doi: 10.2215/CJN.03800609
pubmed: 20966123
Savin VJ, Sharma M, Zhou J, et al. Renal and hematological effects of CLCF-1, a B-Cell-stimulating cytokine of the IL-6 family. J Immunol Res. 2015;2015:714964. https://doi.org/10.1155/2015/714964 .
doi: 10.1155/2015/714964
pubmed: 26146641
pmcid: 4471311
Sharma M, Zhou J, Gauchat JF, et al. Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res. 2015;166(4):384–98. https://doi.org/10.1016/j.trsl.2015.03.002 .
doi: 10.1016/j.trsl.2015.03.002
pubmed: 25843671
pmcid: 4569535
Chebotareva N, Vinogradov A, Cao V, et al. Serum levels of plasminogen activator urokinase receptor and cardiotrophin-like cytokine factor 1 in patients with nephrotic syndrome. Clin Nephrol. 2022;97(2):103–10. https://doi.org/10.5414/CN110514 .
doi: 10.5414/CN110514
pubmed: 34779387
Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clin Chem Lab Med. 2014;52(12):1695–727. https://doi.org/10.1515/cclm-2013-0358 .
doi: 10.1515/cclm-2013-0358
pubmed: 23940067
Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it’s not just about lipid transport anymore. Trends Endocrinol Metab. 2011;22(1):9–15. https://doi.org/10.1016/j.tem.2010.10.001 .
doi: 10.1016/j.tem.2010.10.001
pubmed: 21067941
Jacobs-Cachá C, Puig-Gay N, Helm D, et al. A misprocessed form of apolipoprotein A-I is specifically associated with recurrent focal segmental glomerulosclerosis. Sci Rep. 2020;10(1):1159. https://doi.org/10.1038/s41598-020-58197-y .
doi: 10.1038/s41598-020-58197-y
pubmed: 31980684
pmcid: 6981185
Lopez-Hellin J, Cantarell C, Jimeno L, et al. A form of apolipoprotein a-I is found specifically in relapses of focal segmental glomerulosclerosis following transplantation. Am J Transpl. 2013;13(2):493–500. https://doi.org/10.1111/j.1600-6143.2012.04338.x .
doi: 10.1111/j.1600-6143.2012.04338.x
Puig-Gay N, Jacobs-Cacha C, Sellarès J, et al. Apolipoprotein A-Ib as a biomarker of focal segmental glomerulosclerosis recurrence after kidney transplantation: diagnostic performance and assessment of its prognostic value - a multi-centre cohort study. Transpl Int. 2019;32(3):313–22. https://doi.org/10.1111/tri.13372 .
doi: 10.1111/tri.13372
pubmed: 30411406
Nielsen R, Christensen EI, Birn H. Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease. Kidney Int. 2016;89(1):58–67. https://doi.org/10.1016/j.kint.2015.11.007 .
doi: 10.1016/j.kint.2015.11.007
pubmed: 26759048
Beaudreuil S, Zhang X, Herr F, et al. Circulating CASK is associated with recurrent focal segmental glomerulosclerosis after transplantation. PLoS ONE. 2019;14(7):e0219353. https://doi.org/10.1371/journal.pone.0219353 .
doi: 10.1371/journal.pone.0219353
pubmed: 31356645
pmcid: 6663006
Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol. 2003;7(4):255–9. https://doi.org/10.1007/s10157-003-0259-6 .
doi: 10.1007/s10157-003-0259-6
pubmed: 14712353
Zhang X, Herr F, Vernochet A, et al. CASK, the Soluble glomerular permeability factor, is secreted by macrophages in patients with recurrent focal and Segmental Glomerulo-Sclerosis. Front Immunol. 2020;11:875. https://doi.org/10.3389/fimmu.2020.00875 .
doi: 10.3389/fimmu.2020.00875
pubmed: 32477353
pmcid: 7235163
Ramanathan K, Padmanabhan G. MiRNAs as potential biomarker of kidney diseases: a review. Cell Biochem Funct. 2020;38(8):990–1005. https://doi.org/10.1002/cbf.3555 .
doi: 10.1002/cbf.3555
pubmed: 32500596
Gebeshuber CA, Kornauth C, Dong L, Sierig R, et al. Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nat Med. 2013;19(4):481–7. https://doi.org/10.1038/nm.3142 .
doi: 10.1038/nm.3142
pubmed: 23502960
Wang L, Wang J, Wang Z, et al. Higher urine exosomal miR-193a is Associated with a higher probability of primary focal segmental glomerulosclerosis and an increased risk of poor prognosis among children with nephrotic syndrome. Front Cell Dev Biol. 2021;9:727370. https://doi.org/10.3389/fcell.2021.727370 .
doi: 10.3389/fcell.2021.727370
pubmed: 34708038
pmcid: 8542839
Cruzado JM, Manonelles A, Rayego S et al. Colony stimulating factor-1 receptor drives glomerular parietal epithelial cell activation in focal segmental glomerulosclerosis. Kidney Int. 2024;28:S0085-2538(24)00164-9. https://doi.org/10.1016/j.kint.2024.02.010
Bharati J, Chander PN, Singhal PC. Parietal epithelial cell behavior and its modulation by microRNA-193a. Biomolecules. 2023;13(2):266. https://doi.org/10.3390/biom13020266 .
doi: 10.3390/biom13020266
pubmed: 36830635
pmcid: 9953542
Kumar V, Paliwal N, Ayasolla K, et al. Disruption of APOL1-miR193a Axis induces disorganization of Podocyte actin Cytoskeleton. Sci Rep. 2019;9(1):3582. https://doi.org/10.1038/s41598-019-39376-y .
doi: 10.1038/s41598-019-39376-y
pubmed: 30837512
pmcid: 6401370
Lv LL, Feng Y, Wu M, et al. Exosomal miRNA-19b-3p of tubular epithelial cells promotes M1 macrophage activation in kidney injury. Cell Death Differ. 2020;27(1):210–26. https://doi.org/10.1038/s41418-019-0349-y .
doi: 10.1038/s41418-019-0349-y
pubmed: 31097789
Müller-Deile J, Dannenberg J, Schroder P, et al. Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases. Kidney Int. 2017;92(4):836–49. https://doi.org/10.1016/j.kint.2017.03.005 .
doi: 10.1016/j.kint.2017.03.005
pubmed: 28476557
pmcid: 5658661
Liu G, He L, Yang X, et al. MicroRNA-155-5p aggravates Adriamycin-Induced Focal Segmental Glomerulosclerosis through Targeting Nrf2. Nephron. 2023;147(2):108–19. https://doi.org/10.1159/000525233 .
doi: 10.1159/000525233
pubmed: 35728579
Xu X, Qu S, Zhang C, et al. CD8 T cell-derived exosomal mir-186-5p elicits renal inflammation via activating tubular TLR7/8 Signal Axis. Adv Sci (Weinh). 2023;10(25):e2301492. https://doi.org/10.1002/advs.202301492 .
doi: 10.1002/advs.202301492
pubmed: 37395441
He K, Zhou X, Zhao J, et al. Identification and functional mechanism Verification of Novel MicroRNAs Associated with the fibrosis progression in chronic kidney disease. Biochem Genet. 2024. https://doi.org/10.1007/s10528-024-10688-7 .
doi: 10.1007/s10528-024-10688-7
pubmed: 38877158
Roberts AB, Kim SJ, Noma T et al. Multiple forms of TGF-beta: distinct promoters and differential expression. Ciba Found Symp. 1991;157:7–15. https://doi.org/10.1002/9780470514061.ch2
Sureshbabu A, Muhsin SA, Choi ME. TGF-β signaling in the kidney: profibrotic and protective effects. Am J Physiol Ren Physiol. 2016;310(7):F596–606. https://doi.org/10.1152/ajprenal.00365.2015 .
doi: 10.1152/ajprenal.00365.2015
Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998;93(7):1159–70. https://doi.org/10.1016/s0092-8674(00)81460-9 .
doi: 10.1016/s0092-8674(00)81460-9
pubmed: 9657149
Wrana JL, Attisano L, Wieser R, et al. Mechanism of activation of the TGF-beta receptor. Nature. 1994;370(6488):341–7. https://doi.org/10.1038/370341a0 .
doi: 10.1038/370341a0
pubmed: 8047140
Nakao A, Imamura T, Souchelnytskyi S, et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 1997;16(17):5353–62. https://doi.org/10.1093/emboj/16.17.5353 .
doi: 10.1093/emboj/16.17.5353
pubmed: 9311995
pmcid: 1170167
Massagué J, Wotton D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J. 2000;19(8):1745–54. https://doi.org/10.1093/emboj/19.8.1745 .
doi: 10.1093/emboj/19.8.1745
pubmed: 10775259
pmcid: 302010
Choi ME, Ding Y, Kim SI. TGF-β signaling via TAK1 pathway: role in kidney fibrosis. Semin Nephrol. 2012;32(3):244–52. https://doi.org/10.1016/j.semnephrol .
doi: 10.1016/j.semnephrol
pubmed: 22835455
pmcid: 3407377
Singhirunnusorn P, Suzuki S, Kawasaki N, et al. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein tables 1 and table 2. J Biol Chem. 2005;280(8):7359–68. https://doi.org/10.1074/jbc.M407537200 .
doi: 10.1074/jbc.M407537200
pubmed: 15590691
Epstein FH, Blobe GC, Schiemann WP, et al. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–8. https://doi.org/10.1056/NEJM200005043421807 .
doi: 10.1056/NEJM200005043421807
Feng W, Ruchun Y, Yuewen T. Uncovering pharmacological mechanisms of Phellinus linteus on focal segmental glomeruloscleosis rats through tandem mass tag-based quantitative proteomic analysis, network pharmacology analysis and experimental validation. J Tradit Chin Med. 2023;43(4):744–50.
pubmed: 37454259
Strehlau J, Schachter AD, Pavlakis M, et al. Activated intrarenal transcription of CTL-effectors and TGF-beta1 in children with focal segmental glomerulosclerosis. Kidney Int. 2002;61(1):90–5. https://doi.org/10.1046/j.1523-1755.2002.00090.x .
doi: 10.1046/j.1523-1755.2002.00090.x
pubmed: 11786088
Khalili M, Bonnefoy A, Genest DS. Clinical use of complement, inflammation, and fibrosis biomarkers in Autoimmune Glomerulonephritis. Kidney Int Rep. 2020;5(10):1690–9. https://doi.org/10.1016/j.ekir.2020.07.018 .
doi: 10.1016/j.ekir.2020.07.018
pubmed: 33102961
pmcid: 7569694
Husain S. Renal glomerular expression of WT-1, TGF-β, VEGF, and ET-1 immunostains in Murine models of focal and segmental glomerulosclerosis. Appl Immunohistochem Mol Morphol. 2023;31(8):574–82. https://doi.org/10.1097/PAI.0000000000001146 .
doi: 10.1097/PAI.0000000000001146
pubmed: 37615656
den Braanker DJW, Maas RJH, van Mierlo G, et al. Primary focal segmental glomerulosclerosis plasmas increase lipid droplet formation and Perilipin-2 expression in human podocytes. Int J Mol Sci. 2022;24(1):194. https://doi.org/10.3390/ijms24010194 .
doi: 10.3390/ijms24010194
Shirai Y, Miura K, Ishizuka K, et al. A multi-institutional study found a possible role of anti-nephrin antibodies in post-transplant focal segmental glomerulosclerosis recurrence. Kidney Int. 2024;105(3):608–17. https://doi.org/10.1016/j.kint.2023.11.022 .
doi: 10.1016/j.kint.2023.11.022
pubmed: 38110152